跳至主要内容

Another honor! Medicilon won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023

 On July 4th, the Press Conference of the 2022-2023 Most Influential List of China's Pharmaceutical Industry hosted by the All-China Federation of Industry and Commerce, Pharmaceutical Industry Chamber of Commerce was held in Harbin.  The press conference released the most influential list of China's pharmaceutical industry in 2022-2023.  Medicilon once again won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023 based on its comprehensive strength.

Top 50 Chinese Pharmaceutical R&D.webp

The "Most Influential List of China's Pharmaceutical Industry" by the All-China Federation of Industry and Commerce (ACFIC), Pharmaceutical Chamber of Commerce has become one of the authoritative lists of Chinese pharmaceutical industry.  The ACFIC invited first-class Chinese experts to form a selection team.  The selection adheres to the principles of open collection, objective data, strict screening, and fair selection.  United with a number of well-known Chinese media, focusing on the comprehensive capabilities of participating companies in terms of R&D professional capabilities, integrated service capabilities, professional R&D talent teams and quality assurance system, and good reputation, the 2022-2023 annual list of the most influential series in the pharmaceutical industry will be finally selected.

标签：

评论

发表评论

此博客中的热门博文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services
发表评论
阅读全文

In Vitro Enzyme Activity Assay

  Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+  in vitro  enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...
发表评论
阅读全文

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...
发表评论
阅读全文